Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy

NCT03206645 | Completed Phase 1 DMC FDA Drug

• 1 other identifier: OU-SCC-PTC-001
• Study Type: interventional
• Target: 27
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open-label Phase Ib dose-escalation study to determine the safety, tolerability, and pharmacokinetics of Unesbulin when combined with and following conventional chemotherapy and as maintenance therapy as a capsule (weight based dosing) and a tablet (fixed dosing) in women with epithelial ovarian, fallopian tube or primary peritoneal cancer which is previously untreated.

Conditions

Ovarian Cancer

Outcome Measures

Primary Outcomes (3)

• Maximum tolerated dose and dose limiting toxicities

  To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of Unesbulin in combination with and following conventional chemotherapy and as maintenance as a capsule (weight-based dosing) and a tablet (fixed dosing). Standard chemotherapy will be comprised of carboplatin and weekly paclitaxel. The DLTs will be based on adverse events that occur during administration of the first 2 cycles of combination Unesbulin and chemotherapy (a cycle = 21 days).

  42 days

• Number of patients able to tolerate drug combination

  To examine the tolerability of the combination at the MTD of Unesbulinassessed in combination with standard neoadjuvant chemotherapy.

  3 years

• Phase 2 Dose

  To determine the recommended phase II dose (RP2D) of Unesbulin in combination with standard neoadjuvant chemotherapy.

  3 years

Secondary Outcomes (7)

• Evaluate clinical response

  3 years

• Evaluate pharmacokinetic Area Under the Curve (AUC)

  3 months

• Evaluate pharmacokinetic Maximum Concentration observed (Cmax)

  3 months

• Evaluate pharmacokinetic Time of Maximum Concentration observed (Tmax)

  3 months

• Evaluate pharmacokinetic half life (t1/2)

  3 months

Study Arms (1)

Carboplatin/Paclitaxel + PTC596

EXPERIMENTAL

Carboplatin AUC 6mg/L IV on day 1; Paclitaxel 175mg/m2 IV on day 1; Unesbulin PO, twice a week, on day 1, 4, 8, 11, 15 and 18 per 21-day cycle for the first 3 cycles.

Drug: Unesbulin

Interventions

Unesbulin DRUG

Unesbulin will be given in combination with carboplatin and paclitaxel for up to 7 cycles depending on which cohort the patient is in.

Also known as: PTC596

Carboplatin/Paclitaxel + PTC596

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically documented epithelial ovarian, primary peritoneal or fallopian tube carcinoma or high grade serous adenocarcinoma, endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma,or adenocarcinoma not otherwise specified (N.O.S.)
• Newly diagnosed and be previously untreated
• Adequate bone marrow function, renal function, and hepatic function
• Baseline neuropathy (sensory and motor) less than or equal to Grade 1
• Free of active infection requiring parenteral antibiotics or a serious uncontrolled medical illness or disorder within four weeks of study entry.
• Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration. Continuation of hormone replacement therapy is permitted.
• Have a performance status score of 0, 1, or 2 by Eastern Cooperative Group (ECOG) criteria.
• Patients of childbearing potential must have a negative pregnancy test prior to the study entry and be practicing an effective form of contraception. If applicable, patients must discontinue breastfeeding prior to study entry.

You may not qualify if:

• Prior treatment with Unesbulin or standard of care drugs (cis- or carboplatin or paclitaxel.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to Unesbulin or other agents used in this study.
• Have a clinical requirement for ongoing systemic immunosuppressive therapy such as chronic steroid use not related to chemotherapy administration.
• Receiving treatment for active autoimmune disease including systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis.
• History of other invasive malignancies, with the exception of non-melanoma skin cancer and other specific malignancies within the last three years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy. Patients with concomitant endometrial cancer diagnosed at the time of their ovarian cancer are allowed to participate if the endometrial cancer is FIGO stage IB or less.
• Prior radiotherapy to any portion of the abdominal cavity or pelvis. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted if completed more than three years prior to registration and the patient remains free of recurrent or metastatic disease.
• Prior chemotherapy for any abdominal or pelvic tumor. Patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed three years prior to registration, and that the patient remains free of recurrent or metastatic disease.
• Known active hepatitis, ongoing systemic bacterial, fungal, or viral infection; known human immunodeficiency virus (HIV) infection or acquired-immunodeficiency syndrome (AIDS)-related illness.
• Have concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy.
• Have childbearing potential but not practicing adequate contraception, or pregnant, or breastfeeding.
• History or active CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months prior to study treatment.
• Concomitant therapy with any of the following: other non-study cytotoxic chemotherapy; other investigational therapies.
• Prior bone marrow/hematopoietic stem cell transplantation
• Use of an investigational drug within 4 weeks of dosing in the current study
• History of major surgical procedure within 28 days prior to start of study treatment

Sponsors & Collaborators

• University of Oklahoma: lead
• PTC Therapeutics: collaborator

Study Sites (1)

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States

Location

MeSH Terms

Conditions

Ovarian Neoplasms

Interventions

PTC596

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders

Study Officials

• Kathleen Moore, MD

  University of Oklahoma

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: This trial will utilize a traditional 3+ 3 design with dose escalation.

Study Record Dates

• First Submitted: June 1, 2017
• First Posted: July 2, 2017
• Study Start: August 28, 2017
• Primary Completion: August 11, 2021
• Study Completion: March 31, 2024
• Last Updated: April 23, 2024

Record last verified: 2024-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)